Vaxcyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
November 05, 2024 at 04:06 pm EST
Share
Vaxcyte, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported net loss was USD 103.12 million compared to USD 92.66 million a year ago. Basic loss per share from continuing operations was USD 0.83 compared to USD 0.91 a year ago.
For the nine months, net loss was USD 326.85 million compared to USD 221.47 million a year ago. Basic loss per share from continuing operations was USD 2.78 compared to USD 2.32 a year ago.
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.